News and Trends 7 Sep 2022 TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses TikoMed has announced the inclusion in bioRxiv of an in vitro study examining the ability of the company’s lead drug candidate ILB to inhibit infection of human cells by four serotypes of dengue virus (DENV1-4), two strains of zika virus (African and Asian) and yellow fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Gannex’ first patient dosed in study for treatment of primary biliary cholangitis A study looking at a treatment for primary biliary cholangitis (PBC) has this month (August) enrolled 12 patients and is expected to be completed by the start of this year’s fourth quarter. Gannex Pharma Co., Ltd., owned by Ascletis Pharma Inc., announced yesterday (August 15) that it had finished its first dosing in the […] August 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Stem cell therapy to be used in treatment of long COVID by Panacell Biotech A South Korean biotech company says it will use natural killer (NK) cells, exosomes and brown adipose-derived stem cells (ADSC) as treatment of long COVID. NK cells are a type of immune cell that have granules or small particles that can kill tumor cells or those infected with a virus. Panacell Biotech said they can […] August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Rensselaer researchers make face masks to fight viruses Researchers at Rensselaer Polytechnic Institute in Troy, NY, have developed N95 surgical face masks that are not just barriers to bacteria and viruses, but can also destroy them. The team said the antiviral, antibacterial masks can be worn for longer, creating less waste as the masks do not need to be replaced as frequently. Helen […] June 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email